Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Effect of general anesthesia and intubation on parathyroid levels in normal patients and those with hyperparathyroidism.

Cinamon U, Gavish D, Ovnat Tamir S, Goldfarb A, Ezri T.

Head Neck. 2018 Mar;40(3):555-560. doi: 10.1002/hed.25002. Epub 2017 Nov 11.

PMID:
29130559
2.

[THE IMPACT OF A COMMUNITY INTERVENTION PROGRAM IN ISRAELI WORKSITES TO REDUCE THE RISK OF CARDIOVASCULAR DISEASES].

Yosefy C, Oliel N, Grosbirt A, Levy D, Gavish D, Dicker D, Viskoper R.

Harefuah. 2016 Aug;155(8):485-489. Hebrew.

PMID:
28530333
3.

Molecular genetics of familial hypercholesterolemia in Israel-revisited.

Durst R, Ibe UK, Shpitzen S, Schurr D, Eliav O, Futema M, Whittall R, Szalat A, Meiner V, Knobler H, Gavish D, Henkin Y, Ellis A, Rubinstein A, Harats D, Bitzur R, Hershkovitz B, Humphries SE, Leitersdorf E.

Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18.

PMID:
28104544
4.

Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.

Oz H, Gavish D, Hass A, Shargorodsky M.

J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):547-52. doi: 10.1177/1470320314566017. Epub 2015 Feb 17.

PMID:
25694056
5.

Does metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease?

Soifer E, Gavish D, Shargorodsky M.

Horm Metab Res. 2015 Jul;47(8):556-9. doi: 10.1055/s-0034-1395652. Epub 2015 Feb 11.

PMID:
25671801
6.

Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health.

Lukich A, Gavish D, Shargorodsky M.

Cardiovasc Diabetol. 2014 Oct 22;13:141. doi: 10.1186/s12933-014-0141-8.

7.

Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease.

Omelchenko E, Gavish D, Shargorodsky M.

J Am Soc Hypertens. 2014 Jun;8(6):376-80. doi: 10.1016/j.jash.2014.03.002. Epub 2014 Mar 13.

PMID:
24794207
8.

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).

Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D.

Cardiovasc Diabetol. 2013 Mar 28;12:53. doi: 10.1186/1475-2840-12-53.

9.

The molecular basis of severe hypertriglyceridemia: from genetic counseling to gene therapy.

Gavish D.

Isr Med Assoc J. 2013 Jan;15(1):43. No abstract available.

10.

Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.

Shirin H, Sharvit E, Aeed H, Gavish D, Bruck R.

World J Gastroenterol. 2013 Jan 14;19(2):241-8. doi: 10.3748/wjg.v19.i2.241.

11.

MEasuring Nutrition risk in hospitalized patients: MENU, a hospital-based prevalence survey.

Giryes S, Leibovitz E, Matas Z, Fridman S, Gavish D, Shalev B, Ziv-Nir Z, Berlovitz Y, Boaz M.

Isr Med Assoc J. 2012 Jul;14(7):405-9.

12.

[Prevention and treatment of atherosclerosis and cardiovascular diseases].

Knobler H, Bitzur R, Gavish D, Rubinstein A, Henkin Y, Chajek-Shaul T, Harats D.

Harefuah. 2012 May;151(5):281-8, 319, 318. Hebrew.

PMID:
22844732
13.

Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?

Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D.

Cardiovasc Diabetol. 2012 Jun 7;11:61. doi: 10.1186/1475-2840-11-61.

14.

Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load.

Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M.

Exp Diabetes Res. 2012;2012:250621. doi: 10.1155/2012/250621. Epub 2011 Dec 27.

15.

Intensification of diabetes treatment with long-acting insulin shows no benefit over other diabetes treatment.

Wainstein J, Leibovitz E, Segal T, Gavish D.

Isr Med Assoc J. 2011 Sep;13(9):537-41.

16.

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.

Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y.

Am J Cardiol. 2009 Jul 1;104(1):74-81. doi: 10.1016/j.amjcard.2009.02.047.

PMID:
19576324
17.

Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis?

Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N.

Int J Obes (Lond). 2009 May;33(5):553-8. doi: 10.1038/ijo.2009.37. Epub 2009 Feb 24.

PMID:
19238157
18.

Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women.

Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M.

Atherosclerosis. 2009 Jun;204(2):608-11. doi: 10.1016/j.atherosclerosis.2008.10.024. Epub 2008 Oct 31.

PMID:
19062016
19.

Monitored anaesthesia care in the elderly: guidelines and recommendations.

Ekstein M, Gavish D, Ezri T, Weinbroum AA.

Drugs Aging. 2008;25(6):477-500. Review.

PMID:
18540688
20.

Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.

Luckish A, Cernes R, Boaz M, Gavish D, Matas Z, Fux A, Shargorodsky M.

Bone. 2008 Aug;43(2):279-83. doi: 10.1016/j.bone.2008.03.030. Epub 2008 Apr 22.

PMID:
18515205
21.

Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients.

Mashavi M, Hanah R, Boaz M, Gavish D, Matas Z, Fux A, Shargorodsky M.

Atherosclerosis. 2008 Aug;199(2):362-7. doi: 10.1016/j.atherosclerosis.2007.11.037. Epub 2008 Jan 18.

PMID:
18206891
22.

Childhood obesity/overweight: early diagnosis to prevent premature cardiovascular disease.

Gavish D.

Isr Med Assoc J. 2007 Nov;9(11):813. No abstract available.

23.

Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus.

Shor M, Boaz M, Gavish D, Wainshtein J, Matas Z, Shargorodsky M.

Am J Cardiol. 2007 Dec 15;100(12):1767-70.

PMID:
18082523
24.

Cost-utility analysis of a national project to reduce hypertension in Israel.

Yosefy C, Ginsberg G, Viskoper R, Dicker D, Gavish D.

Cost Eff Resour Alloc. 2007 Nov 28;5:16.

25.

Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.

Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D.

Ann N Y Acad Sci. 2007 Jun;1108:24-34. Erratum in: Ann N Y Acad Sci. 2007;1114:464. Shargorodsky, Marina [added].

PMID:
17893967
26.

Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.

Shargorodsky M, Michaelova K, Boaz M, Gavish D, Zimlichman R.

Diabet Med. 2007 Nov;24(11):1254-60. Epub 2007 Aug 24.

PMID:
17725634
28.

Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.

Stein EA, Marais AD, Ducobu J, Farnier M, Gavish D, Hauner H, Kaplan AJ, Le Maulf F, Melezínková H.

J Clin Lipidol. 2007 Aug;1(4):287-99. doi: 10.1016/j.jacl.2007.07.004.

PMID:
21291693
29.

High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.

Shargorodsky M, Hass E, Boaz M, Gavish D, Zimlichman R.

Atherosclerosis. 2008 Mar;197(1):303-10. Epub 2007 Jun 22.

PMID:
17588581
30.

Proper insertion depth of endotracheal tubes in adults by topographic landmarks measurements.

Evron S, Weisenberg M, Harow E, Khazin V, Szmuk P, Gavish D, Ezri T.

J Clin Anesth. 2007 Feb;19(1):15-9.

PMID:
17321921
31.

Takotsubo cardiomyopathy after general anesthesia for eye surgery.

Gavish D, Rozenman Y, Hafner R, Bartov E, Ezri T.

Anesthesiology. 2006 Sep;105(3):621-3. No abstract available.

PMID:
16931998
32.
33.

The effect of a rapid weight loss induced by laparoscopic adjustable gastric banding on arterial stiffness, metabolic and inflammatory parameters in patients with morbid obesity.

Shargorodsky M, Fleed A, Boaz M, Gavish D, Zimlichman R.

Int J Obes (Lond). 2006 Nov;30(11):1632-8. Epub 2006 Mar 21.

PMID:
16552402
34.

9-cis beta-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients.

Shaish A, Harari A, Hananshvili L, Cohen H, Bitzur R, Luvish T, Ulman E, Golan M, Ben-Amotz A, Gavish D, Rotstein Z, Harats D.

Atherosclerosis. 2006 Nov;189(1):215-21. Epub 2006 Jan 18.

PMID:
16413556
35.

Beyond guidelines: achieving the optimum in LDL cholesterol control.

Leibovitz E, Bitzur R, Harats D, Gavish D.

Curr Opin Lipidol. 2005 Dec;16(6):635-9. Review.

PMID:
16276241
36.

Non-conventional diagnostic tools: do we really need them?

Gavish D.

Isr Med Assoc J. 2005 Oct;7(10):653. No abstract available.

37.

[Lack of treatment continuance: an obstacle for controlling blood pressure].

Leibovitz E, Hertsog D, Oren S, Gavish D.

Harefuah. 2005 Jul;144(7):467-70, 528, 527. Hebrew.

PMID:
16082896
38.

Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: results of the HOLEM study.

Harats D, Leibovitz E, Maislos M, Wolfovitz E, Chajek-Shaul T, Leitersdorf E, Gavish D, Gerber Y, Goldbourt U; HOLEM Study Group.

Isr Med Assoc J. 2005 Jun;7(6):355-9.

39.
40.

Persistent anemia in otherwise asymptomatic severe aortic stenosis: a possible indication for valve replacement?

Leibovitz E, Harpaz D, Elly I, Klepfish A, Gavish D.

Isr Med Assoc J. 2004 Jul;6(7):400-2.

42.

The Ashkelon Hypertension Detection and Control Program (AHDC Program): a community approach to reducing cardiovascular mortality.

Yosefy C, Dicker D, Viskoper JR, Tulchinsky TH, Ginsberg GM, Leibovitz E, Gavish D.

Prev Med. 2003 Dec;37(6 Pt 1):571-6.

PMID:
14636790
43.

Risk factor profile and achievement of treatment goals among hypertensive patients from the Israeli Blood Pressure Control (IBPC) program--initial cost utility analysis.

Yosefy C, Ginsberg GM, Dicker D, Viskoper JR, Tulchinsky TH, Leibovitz E, Gavish D; IBPC Investigators.

Blood Press. 2003;12(4):225-31.

PMID:
14596359
44.

Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.

Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D.

Am J Hypertens. 2003 Sep;16(9 Pt 1):715-8.

PMID:
12944027
45.

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.

Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R.

Am J Hypertens. 2003 Aug;16(8):617-22. Erratum in: Am J Hypertens. 2003 Oct;16(10):894. Wainstein, Gulio [corrected to Wainstein, Julio]; Gavish, Eyal [corrected to Gavish, Dov]; Leibovitz, Ziporah [corrected to Leibovitz, Eyal]; Matas, Dov [corrected to Matas, Ziporah].

PMID:
12878365
46.

Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension.

Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R.

Am J Hypertens. 2002 Dec;15(12):1087-91.

PMID:
12460705
47.

Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.

Gavish D, Leibovitz E, Elly I, Shargorodsky M, Zimlichman R.

Isr Med Assoc J. 2002 Sep;4(9):694-7.

49.

Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.

Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D.

Am J Hypertens. 2001 Nov;14(11 Pt 1):1096-8.

PMID:
11724206
50.

[Atherosclerosis as an autoimmune disease].

Gavish D, Leibovitz E.

Harefuah. 2001 Oct;140(10):987, 990. Hebrew.

PMID:
11681139

Supplemental Content

Loading ...
Support Center